Use of Inhaled Iloprost in an Infant With Bronchopulmonary Dysplasia and Pulmonary Artery Hypertension.
10.4070/kcj.2009.39.8.343
- Author:
Seung Kyung HWANG
1
;
Yung Chul O
;
Nam Su KIM
;
Hyun Kyung PARK
;
Myung Kul YUM
Author Information
1. Department of Pediatrics, College of Medicine, Hanyang University, Seoul, Korea. namsukim@hanyang.ac.kr
- Publication Type:Case Report
- Keywords:
Pulmonary hypertension;
Bronchopulmonary dysplasia;
Iloprost
- MeSH:
Adult;
Bronchopulmonary Dysplasia;
Cyclic Nucleotide Phosphodiesterases, Type 5;
Echocardiography;
Humans;
Hypertension;
Hypertension, Pulmonary;
Iloprost;
Infant;
Infant, Newborn;
Infant, Premature;
Intensive Care, Neonatal;
Nitric Oxide;
Oxygen;
Piperazines;
Pulmonary Artery;
Purines;
Sulfones;
Ventilation;
Sildenafil Citrate
- From:Korean Circulation Journal
2009;39(8):343-345
- CountryRepublic of Korea
- Language:English
-
Abstract:
Pulmonary artery hypertension is a common cardiovascular complication in preterm infants with bronchopulmonary dysplasia which is associated with increased morbidity and mortality. Inhaled iloprost is used as a therapeutic option in pulmonary hypertension, especially in adults. There have been but a few reports on the use of iloprost for neonates and infants. We report the case of a 5 month-old-male infant who received neonatal intensive care for 4 months due to respiratory distress syndrome and prematurity, during which he developed bronchopulmonary dysplasia. Echocardiography showed severe pulmonary hypertension. The initial treatment included respiratory support with high frequency oscillatory ventilation (HFOV); however, his clinical condition did not improve. Inhaled iloprost with sildenafil, an oral phosphodiesterase-5 inhibitor, was thus used. With the administration of iloprost and sildenafil, his condition improved and he was weaned from oxygen. Our clinical experience suggests that iloprost is a promising therapy for pulmonary hypertension, especially when inhaled nitric oxide is unavailable.
